What is Evofem?
Evofem Biosciences, Inc. operates at the intersection of biotechnology and consumer health, focusing on the development and commercialization of novel products designed to address significant gaps in women's sexual and reproductive health. The company distinguishes itself through a patient-centric approach, aiming to disrupt traditional healthcare paradigms by offering accessible, innovative solutions. By prioritizing research and development alongside strategic market entry, Evofem seeks to empower women with greater control over their health outcomes, positioning itself as a vital entity in the broader life sciences ecosystem.
How much funding has Evofem raised?
Evofem has raised a total of $154.8M across 6 funding rounds:
Private Equity
$25M
Series C
$20.6M
Series D
$25M
Other Financing Round
$80M
Stock Offering
$3.3M
Stock/Share Issuance
$925K
Private Equity (2009): $25M with participation from Undisclosed
Series C (2012): $20.6M led by Alta Partners, AMOREPACIFIC US, RMI Partners, and RUSNANO
Series D (2016): $25M supported by Woodford Investment Management
Other Financing Round (2019): $80M featuring PDL, Woodford Investment Management, and Invesco Asset Management
Stock Issuance/Offering (2024): $3.3M backed by Aditx
Stock/Share Issuance (2025): $925K, investors not publicly disclosed
Key Investors in Evofem
Woodford Investment Management
Woodford Investment Management is a financial services firm that was involved in managing various investment funds, including the Woodford Equity Income Fund and Woodford Patient Capital Trust.
Invesco Asset Management
Invesco Ltd. is a publicly owned investment manager providing services to retail, institutional, and high-net-worth clients, managing diverse portfolios across global equity and fixed income markets.
Aditx
Aditxt, Inc. is a social innovation platform dedicated to accelerating promising health innovations through an ecosystem of research institutions and industry partners.
What's next for Evofem?
Looking ahead, the strategic deployment of the $925K will likely focus on scaling commercial operations and deepening market penetration. As the company transitions through its current lifecycle stage, the emphasis will remain on optimizing supply chain efficiencies and expanding clinical awareness. The backing from diverse institutional investors provides the necessary runway to navigate regulatory landscapes and sustain long-term growth. Future initiatives are expected to leverage this capital to bolster the company's competitive advantage, ensuring that its innovative health solutions remain at the forefront of the industry while addressing the evolving needs of its target demographic.
See full Evofem company page
